This fall, at a Tedx conference organized in our community, Mark and I had the chance to meet with and hear a talk by Doug Melton — the Harvard professor…
I can’t resolve to keep my fasting blood sugars between 70 – 110 mg/dL every morning because there are more variables in play than simply my resolve. But there is a “CAN.” What I can resolve to do is test my blood sugar every single morning and make solid decisions based on that number, whatever it may be.
I just got home from the 2014 Medtronic Diabetes Advocate Forum (twitter: #medtronicDAF), a yearly event where Medtronic invites a group of diabetes…
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca and Bristol-Myers Squib new type 2 diabetes treatment, Farxiga (dapagliflozin), a once-daily oral treatment indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
The FDA has granted orphan drug designation for the DiaVacs's type 1 diabetes therapy, DV-0100. The therapy halt’s the body’s autoimmune reaction against the pancreatic islet cells which are responsible for producing insulin, thus allowing them to produce insulin normally and reversing the trajectory of the disease.
What’s worse than having diabetes? I would have to say that having diabetes and battling laryngitis.
It couldn’t have hit me at a more inconvenient…
This flavorful sausage and egg low carb breakfast bake is a perfect brunch item, and it makes a great dinner too. You can even make it ahead of time…
I have no doubt that HelpAround will benefit the diabetes community. Our lives depend on supplies, after all, but with our busy lifestyles and scattered minds, forgetting something is a real risk. As we begin to use HelpAround, other communities will learn and become inspired by the solidarity among people with diabetes.
According to FDA MedWatch, Nipro Diagnostics has initiated a voluntary recall and replacement of a limited number of TRUEbalance and TRUEtrack Blood Glucose Meters distributed both in the United States and outside the United States.
Most of the diabetes products we thought would be introduced in 2013 did not make it to the U.S. market. We're optimistic that some of those products will be available this year. Some, however, like Abbott's Navigator 2, still seem far off.